<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01264783</url>
  </required_header>
  <id_info>
    <org_study_id>11.1.1.H1</org_study_id>
    <nct_id>NCT01264783</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of RNS60 Given by IV to Healthy Subjects</brief_title>
  <official_title>Phase I, Double-blind, Randomized, Placebo-controlled, Single-center Study to Assess the Safety and Tolerability of RNS60 Administered Intravenously to Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Revalesio Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Revalesio Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and tolerability of RNS60 administered
      intravenously to healthy subjects. 12 subjects will receive RNS60 or placebo at three
      escalating rates for 48 hours for each rate.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability</measure>
    <time_frame>6 days</time_frame>
    <description>Safety and tolerability of RNS60 administered by IV infusion to healthy volunteers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarkers</measure>
    <time_frame>6 days</time_frame>
    <description>Analysis of blood samples for various biomarkers</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Myocardial Infarct</condition>
  <arm_group>
    <arm_group_label>RNS60</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RNS60</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RNS60</intervention_name>
    <description>RNS60 for intravenous administration</description>
    <arm_group_label>RNS60</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% normal saline for injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males between 18-55 years

          -  Minimum body weight of 60 kg

          -  BMI of 18-32 kg/m2

          -  Able to execute informed written consent

        Exclusion Criteria:

          -  A chronic or acute disease that might interfere with the evaluation of the safety of
             RNS60

          -  Current or prior malignancies (excluding history of treated non-melanoma skin
             carcinoma)

          -  Positive viral serology test for HBsAG, Hep C antibody, Hep A IgM, or HIV

          -  Use of any prescription medications within 2 weeks of the first day of dosing

          -  Significant organ dysfunction, including cardiac, renal, liver, CNS, pulmonary,
             vascular, GI, endocrine or metabolic

          -  Treatment with monoclonal antibody therapy within 5 half-lives prior to the first dose
             of study medication

          -  Treatment with any investigational drugs or therapies within 30 days (or 5 half-lives,
             whichever is greater) prior to the first dose of study medication

          -  Abnormal pre-admission vital signs, physical exam, clinical laboratory, or any safety
             variable considered clinically significant for this population by the PI

          -  Subject is considering or has scheduled any surgical procedure during participation in
             study

          -  History of alcohol and/or dug abuse within 1 year prior to first dose of study
             medication

          -  Subject has donated plasma or blood within 30 days prior to first dose of study
             medication

          -  Subject requires treatment with any medications, either prescription or
             nonprescription, including dietary supplements or herbal medications, within 14 days
             prior to the first dose of study medication. Exceptions are nonprescription topical
             medications (that are not systemically absorbed), acetaminophen, or vitamins at
             recommended daily doses (not mega dose vitamins)

          -  A positive qualitative urine drug or alcohol test

          -  Concurrent enrollment in any other clinical trial

          -  Subject is judged by PI or Medical Monitor to be inappropriate for the study -

          -  Subject has Gilbert's syndrome

          -  Subject has estimated creatinine clearance at screening of &lt;90 mL/min.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kelly Craven, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quintiles, Inc.</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2010</study_first_submitted>
  <study_first_submitted_qc>December 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2010</study_first_posted>
  <last_update_submitted>September 30, 2011</last_update_submitted>
  <last_update_submitted_qc>September 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

